Cutaneous complications of erlotinib in the treatment of non-small cell lung cancer

被引：0
|
作者：
Preda, V. [1 ]
Mann, S. [2 ]
Lee, S. [3 ]
机构：
[1] Skin & Canc Fdn Australia, Darlinghurst, NSW 2010, Australia
[2] Histopath, Sydney, NSW, Australia
[3] Univ Sydney, Sydney, NSW 2006, Australia
来源：
HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY | 2008年 / 16卷 / 03期
关键词：
acne-like; epithelial; neoplasia; paronychia; xerosis;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
With the rapid expansion in knowledge concerning oncogenesis, targeted pharmacotherapies inhibiting tumour growth are emerging. This article alms to raise awareness of the dermatological side-effect profile of erlotinib. Erlotinib is a tyrosine kinase inhibitor of epidermal growth-factor receptor (EGFR) and is employed in the treatment of non-small cell lung cancer. We describe the dermatological side-effects of erlotinib, with particular attention to the clinical and histological features of its acne-like eruption. Patient comfort and compliance will be significantly enhanced by the early detection and treatment of side-effects from EGFR inhibitors.
引用
收藏
页码：133 / 141
页数：9
相关论文
共 50 条
  • [21] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
  • [22] Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer
    Dermavvan, Josephine Kam Tai
    Gurova, Katerina
    Pink, John
    Dowlati, Afshin
    De, Sarmishtha
    Naria, Goutham
    Sharma, Neelesh
    Stark, George
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [23] Erlotinib in the treatment of non-small-cell lung cancer
    Kyte, J.
    Wilson, P. C.
    Dangoor, A.
    LUNG CANCER, 2012, 75 : S6 - S7
  • [24] MicroRNA markers for erlotinib resistance in non-small cell lung cancer
    Nelson, Kristen
    Ranade, Aarati
    Kashey, Trevor
    Kingsley, Chris
    Weiss, Glen
    CANCER RESEARCH, 2009, 69
  • [25] Use review of Erlotinib in advanced non-small cell lung cancer
    Alvarez-Payero, M.
    Ucha-Samartin, M.
    Martinez-Lopez-de-Castro, N.
    Campelo-Sanchez, E.
    Alvarez-Seoane, J.
    Vazquez-Lopez, C.
    Inaraja-Bobo, M. T.
    Perez Parente, D.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 438 - 438
  • [26] Erlotinib: a new therapeutic approach for non-small cell lung cancer
    Bonomi, P
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (08) : 1395 - 1401
  • [27] Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer
    Brouchet, Laurent
    Bauvin, Eric
    Marcheix, Bertrand
    Bigay-Game, Laurence
    Renaud, Claire
    Berjaud, Jean
    Falcoze, Pierre Emmanuel
    Venissac, Nicolas
    Raz, Dan
    Jablons, David
    Mazieres, Julien
    Dahan, Marcel
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (07) : 626 - 631
  • [28] Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study
    Stathopoulos, G. P.
    Trafalis, D.
    Dimitroulis, J.
    Athanasiou, A.
    Koutantos, J.
    Anagnostopoulos, A.
    ONCOLOGY LETTERS, 2010, 1 (02) : 335 - 338
  • [29] An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer
    Toh, Chee-Keong
    Lee, Pyng
    Chowbay, Balram
    Goh, Jason W. K.
    Mancer, Kent
    Tan, Puay Hoon
    ACTA ONCOLOGICA, 2007, 46 (02) : 256 - 258
  • [30] Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
    Kujtan, Lara
    Subramanian, Janakiraman
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (08) : 1826 - 1829
12345